免疫评分在肿瘤预后及疗效预测中的研究进展

肿瘤的发生发展与肿瘤微环境及宿主免疫状态息息相关.经典的TNM分期在对患者预后评估中渐渐显露不足,这可能与其仅基于肿瘤细胞特征而未能纳入患者免疫因素有关.由此,基于免疫结构这一概念而提出了免疫评分系统,可以在TNM分期的基础上建立更为全面而精准的TNM-I分期.最近,在多项临床试验中发现,免疫评分与TNM分期相比,能更...

Research Progress of Immunoscore in Prediction of Tumor Prognosis and Efficacy to Treatment

The occurrence and development of the tumor are closely associated with the tumor microenvironment (TME) and host immune status. Traditional TNM staging has gradually been insufficient in the assessment of patients’ outcomes, as the TNM system solely evaluated tumor cell characteristics and failed to predict clinical outcomes based on immune factors. Therefore, immunoscore (IS), derived from the concept of immune contexture, was proposed to establish a more comprehensive and accurate TNM-I staging above the TNM staging. Recently, increasing studies have shown that IS can predict the survival outcome and treatment efficacy more accurately than TNM staging. Moreover, IS possess characteristics such as feasibility, convenience, robustness and reproducibility, which make it possible for IS to be used as a biomarker for clinical application, to classify patients better and contribute to developing individualized treatment strategies, ultimately, to improve the overall survival of patients with cancer. This article reviews of the progress of immunoscore in predicting patients’ prognosis and response to therapy among different tumors.